anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Epithelioid glioblastoma (Ep-GBM) is a rare variant of glioblastoma characterized by a high recurrence rate and poor prognosis. Currently, there is no established standard treatment for Ep-GBM. Therefore, we identified 58 Ep-GBM cases to investigate these characteristics and identify the possible prognostic factors of survival. There were 30 male and 28 female patients with a median age of 39 years. Headaches and dizziness were the most common clinical symptom. The tumor is most frequently located in the temporal lobe (36.2%). The positivity rate for BRAF-V600E is 56.9% (33/58), for MGMT is 56.9% (33/58), and for INI-1 is 75% (30/40). Tumor recurrence was observed in 39 patients. The median progression-free survival (PFS) of all patients was 12.7 months, while the median overall survival (OS) was 29.1 months. Additionally, the median survival time after recurrence was 14.3 months. Both univariate and multivariate COX regression analyses revealed that individuals who received more than six cycles of adjuvant oral temozolomide experienced a longer median PFS compared to those who received fewer cycles. Characteristics associated with poorer PFS included tumor dissemination prior to initial surgery. Additionally, both analyses identified tumor dissemination, radiotherapy and adjuvant oral temozolomide as predictors of OS. Notably, for patients with recurrent Ep-GBM, reoperation was shown to significantly increase survival time after recurrence. In conclusion, the standard Stupp regimen is also applicable to patients with Ep-GBM, extending adjuvant oral temozolomide could further improve survival for Ep-GBM patients, reoperation may also prolong survival for recurrent Ep-GBM.
The disclosure provide methods and compositions that use gene editing or gene therapy to treat alpha thalassemia major. The gene editing may be performed  ex vivo  in fetal cells or cells obtained after birth to improve production of globin, with those cells then delivered to the fetus. In other embodiments, gene editing reagents are delivered to the fetus or the patient after birth  in vivo  to edit genes of the alpha-globin cluster and improve globin production. Gene editing system such as CRISPR, TALENs, or ZFNs are used to increase production of alpha, zeta, or theta globin and/or to decrease production of gamma globin. Globin production may be improved by inserting a copy of globin gene or mutating a globin gene to change its expression. Any of the gene editing strategies may be performed in conjunction with delivering to a fetus or patient after birth a therapeutic blood transfusion. Exemplary patients after birth are patients no older than one year of age.
PDIA5 is responsible for modification of disulfide bonds of proteins. However, its impact on the malignant progression of glioblastoma multiforme (GBM) remains unknown. We analyzed the expression and prognostic significance of PDIA5 in cohorts of GBM and clinical samples. The PDIA5 protein was significantly overexpressed in GBM tissues, and higher expression of PDIA5 was statistically associated with a worse prognosis in patients with GBM. Transcriptional data from PDIA5 knockdown GBM cells revealed that downstream regulatory genes of PDIA5 were enriched in malignant regulatory pathways and PDIA5 enhanced the proliferative and invasive abilities of GBM cells. By constructing a PDIA5 CXXC motif mutant plasmid, we found CCAR1 was the vital downstream factor of PDIA5 in regulating GBM malignancy in vitro and in vivo. Additionally, RUNX1 bound to the promoter region of PDIA5 and regulated gene transcription, leading to activation of the PDIA5/CCAR1 regulatory axis in GBM. The RUNX1/PDIA5/CCAR1 axis significantly influenced the malignant behavior of GBM cells. In conclusion, this study comprehensively elucidates the crucial role of PDIA5 in the malignant progression of GBM. Downregulating PDIA5 can mitigate the malignant biological behavior of GBM both in vitro and in vivo, potentially improving the efficacy of treatment for clinical patients with GBM.
PURPOSE: To present our initial experience in the management of multiple ureteral polyps with robotic or laparoscopic ileal ureter replacement (IUR).
METHODS: Eight consecutive patients diagnosed with multiple ureteral polyps underwent robotic or laparoscopic IUR between July 2019 and November 2022. Unilateral IUR was performed in 5 patients with polyps in the left (n = 3) or right (n = 2) side, and 3 patients with bilateral multiple polyps underwent bilateral IUR. Demographic characteristics, perioperative data and follow-up outcomes were prospectively collected.
RESULTS: A cohort of 5 male and 3 female patients (11 ureters) with a mean age of 32.8 ± 11.3 years were included. Among these patients, 5 presented with recurrent flank pain, 1 had hematuria, and 2 were asymptomatic. Four patients experienced prior failed surgical interventions. The mean length of diseased ureter was 11.9 ± 4.7 cm, with more than 10 cm in eight sides. All procedures were performed successfully. The mean operation time was 319 ± 87.6 min with 3 patients who simultaneously underwent intraoperative ureteroscopy. The mean length of ileal graft was 23.8 ± 5.8 cm. During the mean follow-up of 20.4 ± 12.8 months, one major complication, specifically incision infection, and four minor complications, including urinary infection (n = 3) and metabolic acidosis (n = 1), were observed. All patients presented symptom-free, with improved/stabilized hydronephrosis and no signs of restenosis.
CONCLUSION: Robotic or laparoscopic IUR is a feasible, safe, and effective surgical option for patients with long ureteral defects caused by multiple polyps.
The present invention provides methods for reducing A.beta. deposition, A.beta. neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (-)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of A.beta.  deposition, A.beta. neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (-)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter.
Sepsis is a life-threatening immune response to infection in the body, eventually resulting in fatal organ failure. Current methods utilize blood cultures and quick-Sequential-Organ-Failure-Assessment (qSOFA), but there is a need for more accurate and time-sensitive diagnostic methods to improve survival rates. We present a 3D-printed microfluidic chip that bioconjugates antibodies CD69, CD64, and CD25 to channel surfaces to capture sepsis cells in blood samples and validate it with clinical samples (n = 125 septic, n = 10 healthy). Other variables were taken such as healthy volunteer blood samples and patient demographics to validate and confirm our device's diagnostic ability. Statistical differences were found between healthy volunteer and sepsis patient antigen cell counts (CD69 p-value < 0.001, CD64 p-value < 0.004, CD25 p-value < 0.0009), and were confirmed using principal component analysis. Demographics such as length of stay, age, culture results, and need for surgery also factored into sepsis detection on a smaller scale than the antigen cell counts. The receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) of 0.989, 0.988, and 0.992 for CD69, CD64, and CD25, respectively, and a combined biomarker panel of 0.997. Overall, the device performed within a shorter time frame of 4 h compared to standard blood culture tests and was validated for use in detecting sepsis in patients.
A reward-based health activity and exercise mobile application that utilizes an activity monitoring device to track activity data and transmits the data to a mobile device to generate virtual lottery tickets. A mobile application on the mobile device analyzes the activity data and determines if the user has completed the daily health-related goals. If the user completes the daily goal, the user is awarded a virtual lottery ticket reward that can be used for raffles of real prizes. If the user completes exercise and non-exercise goals for consecutive days, the user is awarded with additional streak bonus rewards on an escalating basis. The mobile application can be connected to a communication network whereby users can join teams and other communities to track activity data and compete against other users. A streak saver feature can be provided to allow a user to maintain a streak by performing a task.
Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
The invention discloses a preparation method of artificial nano red blood cells. The microencapsulated artificial nano red blood cells with grain diameter of 200-300nm are formed by nano-assembling and coating modified starch with amphiphilicity outside the hemoglobins. The invention prepares the artificial nano red blood cells by taking the hemoglobins as the oxygen-bearing and oxygen-releasing functional molecules and embedding modified starch microcapsules with amphiphilicity outside the hemoglobins by way of nano-assembling. P50 of the prepared artificial nano red blood cells is 28.5mmHg and the artificial nano red blood cells retain good oxygen-bearing and oxygen-releasing capabilities. The prepared artificial nano red blood cells have no obvious activation to the mice complement system in vitro. The thrombin in the blood plasma is not increased and the testing result of the coagulation factors is qualified. After being injected into the bodies of the mice, the artificial nano red blood cells do not have adverse effect on the blood platelets of the mice and do not cause obvious blood platelet aggregation.
A method and system for providing interactive wellness recommendations is disclosed. The system stores information regarding health profiles, each profile comprised of health data. An individual user health profile can be associated with at least one cohort group. The system obtains individual user health data to develop a user health profile and assigns the user to at least one cohort group based on the user health profile. The system also obtains a user wellness goal. Using the user health profile, a recommendation engine generates a user wellness recommendation for obtaining the user wellness goal based on the user's membership in at least one cohort group by correlating the particular health profile against effective wellness regimens for the user wellness goal as it relates to the cohort group. The user wellness recommendation may then be provided to the user. The user may be continually monitored through any number of methods. As new user health data is obtained, the system can monitor user progress towards their wellness goal and revise the user wellness recommendation based on that progress.
An ocular brachytherapy device, generally comprising a catheter and wire, impregnated with radioactive material, are provided. The wire is formed having a desired treatment shape and size such that it can be placed near an area requiring treatment and effectuate treatment while not affecting adjacent areas. For ease in placement near such areas the wire is preferably formed using materials having properties that permit formation into a desired shape while allowing the wire to be straightened for retraction into the catheter, the shape returning upon removal from the catheter. The wire is preferably impregnated with radioactive material. When the catheter is placed near the area of treatment and the wire is pushed out of the catheter, the wire retakes the desired form and provides a therapeutic radioactive treatment to the area. Preferably, the radioactive material is placed on one edge of the wire, such that the radiation can be directed to the affected area, and non-affected areas can be shielded from radiation.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the BAT trials, 79 of the 2161 (3.7%) of subjects undergoing PCI for treatment of unstable angina and randomized to bivalirudin experienced intracranial bleeding, retroperitoneal bleeding, clinically overt bleeding with a decrease in hemoglobin greater than 3 g/dL or leading to a transfusion of greater than 2 units of blood.

Immunogenicity/Re-Exposure

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bivalirudin in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In in vitro studies, bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.

Among 494 subjects who received bivalirudin in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed. Nine additional patients who had initial positive tests were negative on repeat testing.
The RCCL arm will involve a brief (\~20 minutes) meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will inform the participant of recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (i.e. peer facilitator). The linkage manager will also provide the participant with a list of recovery support service resources.
The invention relates to a preparation method of an andrographis antibacterial cream. The preparation method comprises the following steps of: preparing andrographis extract; preparing an oil phase; preparing a water phase; heating the oil phase and the water phase in water bath with the temperature being 70-80 DEG C, then adding the water phase into the oil phase, stirring, cooling to room temperature, then adjusting pH to be 6.5-7.5, and preparing the cream. The preparation method takes, and the andrographis antibacterial cream of which the main component is the lactone extract of the andrographis is prepared successfully by using the preparation method. The in-vitro antibacterial experiment shows that the cream has good inhibitory action on bacillus thuringiensis, bacillus subtilis, staphylococcus aureus, staphylococcus albus, micrococcus luteus and escherichia coli. The guinea pig skin stimulation and sensitization experiment shows that the cream has no stimulation and sensitization to the skin and is safe and reliable. The cream prepared by the preparation method has strong seepage force, can reach the lesion parts directly, is fast in absorption, quick in action, has no damage to the internal organs, is convenient to use and is safe without toxic or side effects, therefore a high-efficiency and safe external antibacterial dosage form is provided for clinic application.
UNLABELLED: Rapid microbiological diagnosis of the antibiotic susceptibility of Gram-negative bacilli is a priority in clinical microbiology, especially in cases of bacteremia. The rapid advancement of antimicrobial resistance proposes a challenge for empirical antibiotic therapy and shows the need for fast antibiotic susceptibility diagnostics to guide treatments. The QuickMIC System (Gradientech AB, Uppsala, Sweden) is a recently developed rapid diagnostic tool for antibiotic susceptibility testing. Our study evaluates a rapid phenotypic system (QuickMIC) that provides information on the susceptibility of 12 antibiotics against Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloacae, Proteus spp., Citrobacter spp., and Serratia marcescens. A total of 816 antibiotic/microorganism combinations were tested, resulting in eight discrepancies. The concordance between the antibiotics offered by QuickMIC and reference methods (MicroScan WalkAway plus system, Beckman Coulter; Etest (BioMerieux microdilution system (Bruker); Real-time PCR (GeneXpert, Cepheid); and immunochromatography (Biotech) was 99.02%. Time elapsed to obtain a valid minimal inhibitory concentration (MIC) was between 2 and 4 h. The QuickMIC system allows for the early adjustment of antibiotic treatment in these infections. Given the existing limitations of currently available rapid methods, its clinical utility is particularly relevant in the management of P. aeruginosa infections and AmpC-producing Enterobacterales. The use of rapid methods can help diversify antibiotic use and reduce carbapenem consumption.
IMPORTANCE: The rapid diagnosis of antibiotic sensitivity in Gram-negative bacilli is of paramount importance in clinical microbiology, particularly in cases of bacteremia. The escalating challenge of antimicrobial resistance underscores the need for expeditious antibiotic susceptibility diagnostics to guide empirical antibiotic therapy effectively. In light of this, we present our study that evaluates the QuickMIC System, a recently developed rapid diagnostic antibiogram. QuickMIC System, offers a novel approach to phenotypic testing, providing information on the activity of 12 antibiotics against key pathogens, including Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloacae, Proteus spp., Citrobacter spp., and Serratia marcescens. Our investigation involved testing a total of 816 antibiotic/microorganism combinations. The study demonstrated an impressive 99.02% concordance between the QuickMIC System and the reference methods, with only eight discrepancies observed. The time to actionable minimum inhibitory concentration (MIC) ranged between 2 and 4 h, highlighting the system's efficiency in providing rapid results.
ZUBSOLV must be administered whole. Do not cut, chew, or swallow ZUBSOLV. Advise patients not to eat or drink anything until the tablet is completely dissolved. ZUBSOLV should be placed under the tongue until dissolved. The dissolve time for ZUBSOLV varies between individuals, and the median dissolve time observed was 5 minutes. For dosages requiring more than one sublingual tablet, place all tablets in different places under the tongue at the same time. Patients should keep the tablets under the tongue until dissolved; swallowing the tablets reduces the bioavailability of the drug. To ensure consistency in bioavailability, patients should follow the same manner of dosing with continued use of the product.

If a sequential mode of administration is preferred, patients should follow the same manner of dosing to ensure consistency in bioavailability.

Proper administration technique should be demonstrated to the patient. 

Advise patients to do the following after the product has completely dissolved in the oral mucosa: take a sip of water, swish gently around the teeth and gums, and swallow. Advise patients to wait for at least one hour after taking Zubsolv before brushing teeth [see Warnings and Precautions (5.13.), Postmarketing Experience (6.2), Information for Patients (17), and the Medication Guide].
Arteriovenous malformation, or Arteriovenous vascular malformation (AVM) is a congenic disorder characterized by an abnormal connection between veins and arteries, resulting in hemorrhaging and even death. A lack of good animal models has long been an obstacle for identifying effective drugs for neurological AVM treatment. Describe herein is a mouse model for AVM that includes a viable, postnatal animal with a conditional deletion of the activin receptor-like kinase 1 (Alkl;Acvrll). The Alkl-cKO mouse model can be used to identify genes and gene products that are upregulated in subjects suffering from AVM. For example, it has been discovered Agpt2, ILip, and TNF-a, are upregulated in Alkl-cKO compared to controls. Pharmaceutical compositions for treatment of AVM are disclosed. Preferred compositions inhibit or decrease expression of angiogenic and pro-inflammatory factors, such as VEFG, Cox-2, Agpt2, ILip, TNF-α, and matrix metalloproteinases. Methods of determining efficacy of potential AVM therapeutics are also disclosed.
BACKGROUND: Hereditary hearing loss is a rare hereditary condition that has a significant presence in consanguineous populations. Despite its prevalence, hearing loss is marked by substantial genetic diversity, which poses challenges for diagnosis and screening, particularly in cases with no clear family history or when the impact of the genetic variant requires functional analysis, such as in the case of missense mutations and UTR variants. The advent of next-generation sequencing (NGS) has transformed the identification of genes and variants linked to various conditions, including hearing loss. However, there remains a high proportion of undiagnosed patients, attributable to various factors, including limitations in sequencing coverage and gaps in our knowledge of the entire genome, among other factors. In this study, our objective was to comprehensively identify the spectrum of genes and variants associated with hearing loss in a cohort of 106 affected individuals from the UAE.
RESULTS: In this study, we investigated 106 sporadic cases of hearing impairment and performed genetic analyses to identify causative mutations. Screening of the GJB2 gene in these cases revealed its involvement in 24 affected individuals, with specific mutations identified. For individuals without GJB2 mutations, whole exome sequencing (WES) was conducted. WES revealed 33 genetic variants, including 6 homozygous and 27 heterozygous DNA changes, two of which were previously implicated in hearing loss, while 25 variants were novel. We also observed multiple potential pathogenic heterozygous variants across different genes in some cases. Notably, a significant proportion of cases remained without potential pathogenic variants.
CONCLUSIONS: Our findings confirm the complex genetic landscape of hearing loss and the limitations of WES in achieving a 100% diagnostic rate, especially in conditions characterized by genetic heterogeneity. These results contribute to our understanding of the genetic basis of hearing loss and emphasize the need for further research and comprehensive genetic analyses to elucidate the underlying causes of this condition.
Risk Summary

There is no information regarding the presence of topically administered calcipotriene and betamethasone dipropionate in human milk, the effects on the breastfed infant, or the effects on milk production. Concentrations of calcipotriene in plasma are low after topical administration, and therefore, concentrations in human milk are likely to be low [see Clinical Pharmacology (12.3)]. It is not known whether topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Enstilar® Foam and any potential adverse effects on the breastfed child from Enstilar Foam or from the underlying maternal condition.

Clinical Considerations

To minimize potential exposure to the breastfed infant via breast milk, use Enstilar Foam on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply Enstilar Foam directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.4)].